Technical Analysis for TRVN - Trevena, Inc.

Grade Last Price % Change Price Change
grade F 0.7499 -1.13% -0.01
TRVN closed up 1.11 percent on Wednesday, February 19, 2020, on 77 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 11
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical TRVN trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish -1.13%
NR7 Range Contraction -1.13%
Wide Bands Range Expansion -1.13%
Oversold Stochastic Weakness -1.13%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.04%
Outside Day Range Expansion -0.04%
Oversold Stochastic Weakness -0.04%
NR7 Range Contraction -3.86%
Inside Day Range Contraction -3.86%
Oversold Stochastic Weakness -3.86%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the µ-opioid receptor has completed Phase 1b clinical trials to treat moderate to severe acute pain intravenously; TRV734 that is in preclinical studies as a orally administered treatment of moderate to severe acute and chronic pain; and d-opioid receptor G protein biased ligand therapeutics for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.
Pain Organic Compounds Central Nervous System Disorders Analgesics Cell Signaling Pyridines Signal Transduction Treatment Of Central Nervous System Disorders Opioid Acute Heart Failure Thiophenes

Is TRVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.0
52 Week Low 0.6
Average Volume 602,572
200-Day Moving Average 0.94
50-Day Moving Average 0.82
20-Day Moving Average 0.85
10-Day Moving Average 0.79
Average True Range 0.05
ADX 31.35
+DI 8.48
-DI 27.30
Chandelier Exit (Long, 3 ATRs ) 0.83
Chandelier Exit (Short, 3 ATRs ) 0.89
Upper Bollinger Band 0.98
Lower Bollinger Band 0.72
Percent B (%b) 0.15
BandWidth 30.36
MACD Line -0.02
MACD Signal Line -0.01
MACD Histogram -0.0149
Fundamentals Value
Market Cap 45.28 Million
Num Shares 59.7 Million
EPS -1.94
Price-to-Earnings (P/E) Ratio -0.39
Price-to-Sales 0.00
Price-to-Book 1.66
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.80
Resistance 3 (R3) 0.80 0.78 0.80
Resistance 2 (R2) 0.78 0.77 0.78 0.79
Resistance 1 (R1) 0.77 0.76 0.77 0.77 0.79
Pivot Point 0.75 0.75 0.75 0.75 0.75
Support 1 (S1) 0.74 0.74 0.74 0.74 0.73
Support 2 (S2) 0.72 0.73 0.72 0.72
Support 3 (S3) 0.71 0.72 0.72
Support 4 (S4) 0.71